Seres Therapeutics, Inc. (MCRB)
| Market Cap | 67.39M |
| Revenue (ttm) | 789,000 |
| Net Income (ttm) | 5.70M |
| Shares Out | 9.59M |
| EPS (ttm) | 0.64 |
| PE Ratio | 11.09 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,002 |
| Open | 7.45 |
| Previous Close | 7.32 |
| Day's Range | 6.98 - 7.74 |
| 52-Week Range | 6.53 - 29.98 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 14.00 (+99.15%) |
| Earnings Date | May 11, 2026 |
About MCRB
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 99.15% from the latest price.
News
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
Seres Therapeutics to Present at CARB-X Investor Day
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at th...
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track fo...
Seres Therapeutics Transcript: Status update
Management transitions reinforce expertise as the organization focuses on advancing live biotherapeutic programs for inflammatory and immune diseases. Key clinical milestones include an upcoming SER-155 data readout in irEC and ongoing development of SER-603 for IBD, while cost controls and funding efforts aim to extend operations through Q3 2026.
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs...
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activ...
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients
Seres Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing SER-155 for allo-HSCT patients, showing strong phase Ib efficacy and safety, with FDA-aligned phase II plans and significant commercial potential. Expansion into broader indications and new programs like SER-603 for IBD are underway, supported by ongoing partnerships and funding through Q2 next year.
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat...
Seres Therapeutics Earnings Call Transcript: Q3 2025
SER-155 advanced toward phase two for bloodstream infection prevention, with strong phase 1B results and FDA alignment. Q3 saw a return to net income, cost reductions, and a CARB-X grant, while further progress depends on securing additional funding.
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transpl...
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and liv...
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections Liquid formulati...
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from...
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainw...
Seres Therapeutics Earnings Call Transcript: Q2 2025
SER-155 advanced to Phase 2 readiness with strong prior results and global study plans. Q2 net loss narrowed, cash runway extends into Q1 2026, and active efforts are underway to secure capital through partnerships or mergers amid a challenging biotech environment.
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (a...
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and liv...
Seres Therapeutics Announces Leadership Transition
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple p...
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSC...
Seres Therapeutics Earnings Call Transcript: Q1 2025
Q1 2025 saw a return to profitability driven by a $50M Nestlé payment, reduced expenses, and a strong cash position. SER-155 advanced toward phase II, with study initiation dependent on partnership, and received positive regulatory and clinical feedback.
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allog...